tiprankstipranks
Trending News
More News >
Basilea Pharmaceutica (CH:BSLN)
:BSLN
Advertisement

Basilea Pharmaceutica (BSLN) AI Stock Analysis

Compare
5 Followers

Top Page

CH:BSLN

Basilea Pharmaceutica

(BSLN)

Rating:65Neutral
Price Target:
CHF53.00
▲(13.37% Upside)
Basilea Pharmaceutica's overall stock score reflects strong financial performance and positive earnings call highlights, tempered by bearish technical indicators and high liabilities. The stock's valuation suggests potential undervaluation, but caution is advised due to financial pressures and expected revenue declines.
Positive Factors
FDA Approval
The FDA approval of Zevtera for specific indications makes it the only approved MRSA cephalosporin antibiotic for certain infections, giving it a unique market position.
Product Launch
Basilea's antibiotic Zevtera is being launched in the U.S. ahead of schedule, offering potential for early revenue generation from royalties and sales milestones.
Sales Milestone
Cresemba has achieved a sales milestone in Japan and is the highest-selling branded antifungal agent worldwide, reflecting strong market performance.
Negative Factors
Market Penetration Risks
Risks include potential challenges in market penetration for ceftobiprole in the U.S. and setbacks with clinical-stage candidates like fosmanogepix.
Partner Optimization Risks
Risks include inability by Basilea's partners to optimize the value of isavuconazole and ceftobiprole globally.

Basilea Pharmaceutica (BSLN) vs. iShares MSCI Switzerland ETF (EWL)

Basilea Pharmaceutica Business Overview & Revenue Model

Company DescriptionBasilea Pharmaceutica AG is a biopharmaceutical company based in Switzerland that focuses on the development and commercialization of innovative therapies for oncology and infectious diseases. The company specializes in the discovery and development of novel antimicrobial agents and targeted cancer treatments, with a particular emphasis on addressing unmet medical needs in these areas. Its core products include a range of antibiotics and oncology drugs that target specific molecular pathways involved in disease progression.
How the Company Makes MoneyBasilea Pharmaceutica generates revenue primarily through the sale of its pharmaceutical products, including both proprietary and partnered drugs. The company’s revenue model is bolstered by strategic partnerships and collaborations with larger pharmaceutical companies, which often include upfront payments, milestone payments, and royalties based on sales of the partnered products. Additionally, Basilea may receive licensing fees or other revenue from its intellectual property, as well as potential revenues from clinical trial collaborations. The company’s focus on innovative therapies allows it to tap into niche markets with high demand, contributing to its overall earnings.

Basilea Pharmaceutica Earnings Call Summary

Earnings Call Date:Aug 19, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Feb 17, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted strong sales performance and strategic achievements, such as the launch of Zevtera in the U.S. and significant funding secured. However, challenges include decreased net profit due to past tax benefits, rising operating expenses, and an anticipated decline in product revenue due to reduced supply to Pfizer. The overall sentiment suggests a positive outlook with some caution due to financial pressures.
Q2-2025 Updates
Positive Updates
Impressive Sales Growth for Cresemba
Cresemba achieved a 24.8% increase in global in-market sales for the 12 months to March 2025 and a 21.7% increase in royalty income year-on-year.
Strong Financial Performance
Basilea reported a positive operating result of CHF 24 million for the first half of 2025, with total revenue increasing by 36% compared to the first half of 2024.
Secured Additional Funding
Basilea secured USD 39 million in nondilutive funding from BARDA to support the development of antifungal candidates.
Strategic In-Licensing
Basilea in-licensed ceftibuten-ledaborbactam, a Phase III-ready oral antibiotic for complicated urinary tract infections.
Zevtera U.S. Launch
Zevtera was successfully launched in the U.S., marking a key commercial milestone.
Negative Updates
Decrease in Net Profit
Net profit decreased from CHF 20.7 million in the first half of 2024 to CHF 15.8 million in the first half of 2025 due to a onetime income tax benefit in 2024.
Increased Operating Expenses
Operating expenses rose to CHF 55.7 million, mainly due to costs associated with the ongoing fosmanogepix Phase III program.
Expected Decrease in Product Revenue
A 17% reduction in product revenue to about CHF 48 million is anticipated year-on-year due to decreased product supply to Pfizer.
Company Guidance
During the Basilea Pharmaceutica Half Year Results 2025 Conference Call, the company provided updated financial guidance for the year, highlighting a projected total revenue increase to CHF 225 million, up from the previously communicated CHF 220 million. Revenue from Cresemba and Zevtera is expected to reach around CHF 190 million, with a 14% growth in royalty income to CHF 110 million. Operating profit for 2025 is anticipated to be approximately CHF 50 million. R&D expenses are set to rise to CHF 105 million, primarily due to in-licensing ceftibuten-ledaborbactam, adding CHF 15 million in expenses. The company also reported a positive net cash position of CHF 50.7 million as of June 30, 2025, and highlighted the strong performance of Cresemba, with in-market sales reaching USD 612 million, a 25% year-on-year increase.

Basilea Pharmaceutica Financial Statement Overview

Summary
Basilea Pharmaceutica has demonstrated strong revenue growth and improved profitability with a significant net profit margin increase in 2024. The cash flow is robust, with a substantial free cash flow increase. However, balance sheet concerns persist due to high liabilities.
Income Statement
72
Positive
Basilea Pharmaceutica has shown strong revenue growth from 2023 to 2024 with an increase of 32.3%. The gross profit margin decreased from 2023 to 2024 due to a decline in gross profit. However, the net profit margin improved significantly to 37.2% in 2024, indicating better profitability. The EBIT and EBITDA margins also saw significant improvements, indicating enhanced operational efficiency.
Balance Sheet
58
Neutral
The company has improved its balance sheet with positive stockholders' equity in 2024, moving from negative in previous years. The debt-to-equity ratio has improved as equity turned positive, and the equity ratio at 31.4% indicates a stronger financial position. However, high total liabilities relative to assets remain a concern.
Cash Flow
80
Positive
The cash flow statement shows a strong free cash flow growth of 449.6% from 2023 to 2024, indicating robust cash generation. The operating cash flow to net income ratio is healthy, supporting the company's profitability and cash generation capabilities. The free cash flow to net income ratio is also strong, reflecting efficient cash management.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue208.54M157.63M147.76M148.12M127.63M
Gross Profit169.86M130.84M120.96M124.05M103.58M
EBITDA63.13M23.18M26.21M6.72M-2.24M
Net Income77.59M10.45M12.15M-6.83M-14.72M
Balance Sheet
Total Assets257.76M173.29M220.85M247.27M229.79M
Cash, Cash Equivalents and Short-Term Investments120.71M59.90M86.57M149.95M167.28M
Total Debt111.67M128.61M187.14M218.96M242.32M
Total Liabilities176.76M183.29M241.56M305.87M331.84M
Stockholders Equity81.00M-10.00M-20.71M-58.61M-102.05M
Cash Flow
Free Cash Flow72.65M13.21M3.75M-32.88M-56.40M
Operating Cash Flow74.36M14.24M7.06M-32.02M-54.13M
Investing Cash Flow-1.01M-1.03M91.65M3.58M-34.96M
Financing Cash Flow-13.16M-57.30M-45.25M16.64M45.07M

Basilea Pharmaceutica Technical Analysis

Technical Analysis Sentiment
Negative
Last Price46.75
Price Trends
50DMA
50.94
Negative
100DMA
47.72
Negative
200DMA
45.17
Positive
Market Momentum
MACD
-1.55
Positive
RSI
32.38
Neutral
STOCH
5.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BSLN, the sentiment is Negative. The current price of 46.75 is below the 20-day moving average (MA) of 51.49, below the 50-day MA of 50.94, and above the 200-day MA of 45.17, indicating a neutral trend. The MACD of -1.55 indicates Positive momentum. The RSI at 32.38 is Neutral, neither overbought nor oversold. The STOCH value of 5.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:BSLN.

Basilea Pharmaceutica Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
CHF566.94M7.79
58.51%
51
Neutral
$7.83B-0.18-40.10%2.29%21.46%-2.03%
$147.59M-48.90%
51
Neutral
CHF604.47M
67.18%-480.10%
$1.16B-7.82%
$223.64M11.40
$221.34M2.70-93.91%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CH:BSLN
Basilea Pharmaceutica
46.35
0.15
0.32%
MLLCF
Molecular Partners AG
4.22
-1.67
-28.35%
CH:IDIA
Idorsia Ltd
2.70
0.50
22.73%
CSBTF
Kuros Biosciences
31.38
13.45
75.01%
NWPHF
Newron Pharmaceuticals SpA
9.36
0.26
2.86%
SPHDF
Santhera Pharmaceuticals Holding
18.00
6.30
53.85%

Basilea Pharmaceutica Corporate Events

Basilea Secures $39 Million BARDA Funding for Antifungal Drug Development
Jul 8, 2025

Basilea Pharmaceutica announced that the US Biomedical Advanced Research and Development Authority (BARDA) has approved an additional $39 million in funding to support the development of its novel antifungal agents, Fosmanogepix and BAL2062. This funding will aid ongoing and upcoming Phase 3 and Phase 2 studies, addressing the high medical need for new antifungal treatments, especially for patients with weakened immune systems.

The most recent analyst rating on (CH:BSLN) stock is a Buy with a CHF95.00 price target. To see the full list of analyst forecasts on Basilea Pharmaceutica stock, see the CH:BSLN Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 20, 2025